Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats

Nitric oxide (NO) deficiency is associated with development of hypertension. We examined whether melatonin protects against the blood pressure increase is because of the restoration of the NO pathway. Spontaneous hypertensive rats (SHR) and control normotensive Wistar Kyoto (WKY) rats aged 4 weeks were assigned to four groups (N=6 for each group): untreated SHR and WKY, melatonin-treated SHR and WKY. Melatonin-treated rats received 0.01% melatonin in drinking water for 8 wks. All rats were sacrificed at 12 wk of age. SHR had higher blood pressure than WKY, which melatonin prevented. Plasma asymmetric dimethylarginine (ADMA) levels were elevated in SHR, combined with a reduction in plasma L-arginine to ADMA ratio (AAR). In the kidney, L-arginine, ADMA, and AAR were not different between SHR and WKY rats, whereas L-citrulline level was increased in SHR. Melatonin decreased plasma ADMA level and restored plasma AAR. Renal dimethylarginine dimethylaminohydrolase (DDAH, ADMA-metabolizing enzyme) activity was lower in SHR than WKY rats, which melatonin therapy prevented. Also, melatonin elevated both L-arginine and ADMA but reduced L-citrulline level in the kidney in SHR, which was associated with the prevention of reduced renal argininosuccinate lyase (ASL) expression in SHR. Moreover, melatonin reduced the degree of oxidative damaged DNA product, 8- hydroxydeoxyguanosine (8-OHdG) immunostaining in SHR. The observed antihypertensive effects of melatonin in young SHR are because of the restoration of the NO pathway by reduction of plasma ADMA, restoration of plasma AAR, preservation of renal L-Arg availability, and attenuation of oxidative stress.     

Probucol Decreases Asymmetrical Dimethylarginine Level by Alternation of Protein Arginine Methyltransferase I and Dimethylarginine Dimethylaminohydrolase Activity

Hypothesis Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor (NOS), may play an important role in endothelium dysfunction. Probucol, a potent antioxidant drug, may improve endothelium function via reduction of NOS inhibitor level. The present study examined whether the decreased level of ADMA by probucol is related to enhancement of protein arginine methyltransferase I (PRMT I) expression and reduction of dimethylarginine dimethylaminohydrolase (DDAH) activity. Methods Endothelial cells were cultured and used for all these studies. ADMA concentration and DDAH activity were determined by HPLC. Expression of PRMT I and eNOS were characterized by western blot. Results Pretreatment with oxidized-low density lipoprotein (ox-LDL) (10, 30 or 100 μg/ml) or lysophosphatidylcholine (LPC) (1.0, 2.5 or 5.0 μg/ml) for 12, 24 or 48 h markedly increased the activity of lactate dehydrogenase (LDH) in cultured endothelial cell. Incubation ofendothelial cells with ox-LDL (100 μg/ml) or LPC (5.0 μg/ml) for 48 h significantly increased the expression of PRMT I, and levels of MDA and ADMA, and decreased the concentration of nitrite/nitrate, the expression of eNOS and the activity of DDAH. Probucol significantly decreased the level of ADMA, concomitantly with reduction of PRMT I expression and elevation of DDAH activity and up-regulation of eNOS expression. Conclusion In summary, the present results suggest that the protective effect of probucol on endothelium is related to reduction of ADMA concentration by inhibition of PRMT I expression and enhancement of DDAH activity.     

Estradiol,acting through estrogen receptor alpha,restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase. ADMA accumulation, mainly due to a decreased dimethylarginine dimethylaminohydrolase (DDAH) activity, has been related to the development of cardiovascular diseases. We investigate whether estradiol prevents the changes induced by oxidized low density lipoprotein (oxLDL) on the DDAH/ADMA/NO pathway in human umbilical artery endothelial cells (HUAEC). HUAEC were exposed to estradiol, native LDL (nLDL), oxLDL and their combinations for 24 h. In some experiments, cells were also exposed to the unspecific estrogen receptor (ER) antagonist ICI 182780, the specific ERα antagonist MPP or specific agonists for ERα, ERβ and GPER. ADMA concentration was measured by HPLC and concentration of NO by amperometry. Protein expression and DDAH activity were measured by immunoblotting and an enzymatic method, respectively. oxLDL, but not nLDL, increased ADMA concentration with a concomitant decrease on DDAH activity. oxLDL reduced eNOS protein and NO production. Estradiol alone had no effects on DDAH/ADMA/NO pathway, but increased the attenuated endothelial NO production induced by oxLDL by reduction in ADMA and preventing loss of eNOS protein levels. ICI 182780 and MPP completely abolished these effects of estradiol on oxLDL-exposed cells. ERα agonist, but not ERβ and GPER agonists, mirrored estradiol effects on NO production. In conclusion, estradiol restores (1) DDAH activity, and therefore ADMA levels, and (2) NO production impaired by oxLDL in HUAEC acting through ERα.     

Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients

AIM：To analyze the change of dimethylarginine plasma levels in cirrhotic patients receiving transjugular intrahepatic portosystemic shunt（TIPS）.METHODS：To determine arginine,asymmetric dimethylarginine（ADMA）,symmetric dimethylarginine（SDMA）,and nitric oxide（NO） plasma levels,blood samples were collected from the superior cava,hepatic,and portal vein just before,directly after,and 3 mo after TIPS-placement.RESULTS：A significant increase in the arginine/ADMA ratio after TIPS placement was shown.Moreover,TIPS placement enhanced renal function and thereby decreased systemic SDMA levels.In patients with renal dysfunction before TIPS placement,both the arginine/ADMA ratio and creatinine clearance rate increased significantly,while this was not the case in patients with normal renal function before TIPS placement.Hepatic function did not change significantly after TIPS placement and no significant decline in ADMA plasma levels was measured.CONCLUSION：The increase of the arginine/ADMA ratio after TIPS placement suggests an increase in intracellular NO bioavailability.In addition,this study suggests that TIPS placement does not alter dimethylarginine dimethylaminohydrolase（DDAH） activity and confirms the major role of the liver as an ADMA clearing organ.     

Liver plays a central role in asymmetric dimethylargininemediated organ injury

Asymmetric-dimethylarginine(ADMA) competes with L-arginine for each of the three isoforms of nitric oxide synthase:endothelial;neuronal;inducible.ADMA is synthesized by protein methyltransferases followed by proteolytic degradation.ADMA is metabolized to citrulline and dimethylamine,by dimethylarginine dimethylaminohydrolase(DDAH) and enters cells through cationic amino-acid transporters extensively expressed in the liver.The liver plays a crucial role in ADMA metabolism by DDAH-1 and,as has been recently demonstrated,it is also responsible for ADMA biliary excretion.A correlation has been demonstrated between plasma ADMA levels and the degree of hepatic dysfunction in patients suffering from liver diseases with varying aetiologies:plasma ADMA levels are increased in patients with liver cirrhosis,alcoholic hepatitis and acute liver failure.The mechanism by which liver dysfunction results in raised ADMA concentrations is probably due to impaired activity of DDAH due to severe inflammation,oxidative stress,and direct damage to DDAH.High plasma ADMA levels are also relevant as they are associated with the onset of multiorgan failure(MOF).Increased plasma concentration of ADMA was identified as an independent risk factor for MOF in critically-ill patients causing enhanced Intensive Care Unit mortality:a significant reduction in nitric oxide synthesis,leading to malperfusion in various organs,eventually culminating in multi organs dysfunction.     

Antidiabetic drug metformin is effective on the metabolism of asymmetric dimethylarginine in experimental liver injury

AimsWe aimed to investigate the pharmacological efficiency of metformin on asymmetric dimethylarginine (ADMA) metabolism in inflammation caused by the lipopolysaccharide (LPS)/d-galactosamine (d-GalN) treatment.MethodsAdult Sprague-Dawley rats were injected LPS/d-GalN intraperitoneally. One half of the animals was injected metformin (250 mg kg⁻¹ body mass for one week) prior to LPS/d-GalN treatment. Six hours after the LPS/d-GalN injection, livers were removed, and used for the measurements of dimethylarginine dimethylaminohydrolase (DDAH) and myeloperoxidase (MPO) activities, glutathione (GSH), ADMA and arginine levels. Liver tissues were examined histopathologically. The Kruskal–Wallis (posthoc Mann–Whitney U) test was used for the statistics.LPS/d-GalN injections caused liver injury as evidenced by the activities of aminotransferases and arginase. GSH level and DDAH activity were decreased in the liver. Metformin pretreatment alleviated the activity of serum enzymes, and attenuated histopathological lesions caused by LPS/d-GalN injections. LPS/d-GalN-induced inflammation, as confirmed by the increased MPO activity, created an asymmetrical distribution of arginine and ADMA between the tissue and plasma. Metformin decreased tissue ADMA level while it restored the DDAH activity and GSH.ConclusionOur findings showed that metformin administration for one week has a potency to protect liver through regulating ADMA metabolism in LPS/d-GalN-induced injury.     

Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension

Abstract:  The effect of melatonin was investigated in an angiotensin II-dependent renovascular hypertension model in Wistar albino rats by placing a renal artery clip (two-kidney, one-clip; 2K1C), while sham rats did not have clip placement. Starting either on the operation day or 3 wk after the operation, the rats received melatonin (10 mg/kg/day) or vehicle for the following 6 wk. At the end of the nineth week, after blood pressure (BP) and echocardiographic recordings were obtained, plasma samples were obtained to assay lactate dehydrogenase (LDH), creatine kinase (CK), antioxidant capacity (AOC), asymmetric dimethylarginine (ADMA), and nitric oxide (NOx) levels. In the kidney, heart and brain tissues, malondialdehyde (MDA) and glutathione (GSH) levels, superoxide dismutase (SOD), catalase (CAT), myeloperoxidase (MPO) and Na⁺-K⁺ ATPase activities were determined. 2K1C caused an increase in BP and left ventricular (LV) dysfunction. In hypertensive animals LDH, CK, ADMA levels were increased in plasma with a concomitant reduction in AOC and NOx. Moreover, hypertension caused a significant decrease in tissue SOD, CAT, and Na⁺, K⁺-ATPase activities and glutathione content, while MDA levels and MPO activity were increased in all studied tissues. On the other hand, both melatonin regimens significantly reduced BP, alleviated oxidative injury and improved LV function. In conclusion, melatonin protected against renovascular hypertension-induced tissue damage and improved cardiac function presumably due to both its direct antioxidant and receptor-dependent actions, suggesting that melatonin may be of therapeutic use in preventing oxidative stress due to hypertension.     

Changes in the arginine methylation of organ proteins during the development of diabetes mellitus

Aim

In this study, we examined changes in asymmetric dimethylarginine (ADMA), dimethylarginine dimethylaminohydrolase (DDAH), nitric oxide synthesis (NOS), and the arginine methylation of organ proteins during the development of diabetes in mice.

Methods

Db/db mice developed significant obesity and fasting hyperglycemia during diabetogenesis. During diabetogenesis, the expression of ADMA and nNOS was increased, while that of DDAH1 and protein-arginine methyltransferase 1 (PRMT1) was decreased. Additionally, arginine methylation in the liver and adipose tissue was altered during diabetogenesis.

Results

Changes were evident at 75, 60, and 52 kDa in liver tissue and at 38 and 25 kDa in adipose tissue. Collectively, DDAH and ADMA are closely associated with the development of obesity and diabetes, and the arginine methylation levels of certain proteins were changed during diabetes development.

Conclusion

Protein arginine methylation plays a role in the pathogenesis of diabetes.     

Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine

OBJECTIVES: To determine whether alterations of endogenous asymmetric dimethylarginine (ADMA) concentration and dimethylarginine dimethylaminohydrolase (DDAH) activity are involved in endothelial dysfunction induced by glycosylated bovine serum albumin (GBSA) in rats and effects of aminoguanidine on them. METHODS: Endothelium-dependent relaxation of aortic rings from Sprague-Dawley rats after treatment with GBSA in vitro and in vivo was tested. Serum concentrations of ADMA, nitrite/nitrate, and activities of aortic DDAH, nitric oxide synthase (NOS) and superoxide dismutase were measured in GBSA-treated rats. Moreover, serum contents of glycosylated serum protein, and malondialdehyde were also assayed. RESULTS: Endothelium-dependent relaxation was significantly impaired either by incubation of aortic rings with GBSA (1.70mmol/l) in vitro for 60min or by injection of GBSA (35mg/kg/d, i.v.) to normal rats for 4 weeks, and serum ADMA levels were remarkably elevated in GBSA-treated rats, which was accompanied by decreases of nitrite/nitrate concentrations, NOS and DDAH activities. Furthermore, elevated glycosylated serum protein, malondialdehyde levels, and reduced superoxide dismutase activity were also observed in GBSA-treated rats. Treatment with aminoguanidine not only improved impairment of endothelium-dependent relaxation but also prevented elevation of endogenous ADMA, which were concomitant with increases of nitrite/nitrate concentration, NOS and DDAH activity. Serum levels of glycosylated serum protein, malondialdehyde, and vascular superoxide dismutase activity were also normalized after aminoguanidine treatment. CONCLUSIONS: Decreased DDAH activity and elevated endogenous ADMA is implicated in endothelial dysfunction of rats exposed to GBSA. Aminoguanidine can protect endothelium of rat aorta against injury induced by GBSA both in vitro and in vivo.     

Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness

High plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are associated with adverse outcome in critically ill patients. Asymmetric dimethylarginine is released within cells during proteolysis of methylated proteins and is either degraded by dimethylarginine dimethylaminohydrolase (DDAH) or exported to the circulation via cationic amino acid transporters. We aimed to establish the role of DDAH activity in the regulation of tissue and plasma concentrations of ADMA. In 33 critically ill rabbits, we measured DDAH activity in kidney, liver, heart, and skeletal muscle and related these values to concentrations of ADMA in these tissues and in the circulation. Both DDAH activity and ADMA concentration were highest in kidney and lowest in skeletal muscle, with intermediate values for liver and heart. Whereas ADMA content was significantly correlated between tissues (r = 0.40-0.78), DDAH activity was not. Significant inverse associations between DDAH activity and ADMA content were only observed in heart and liver. Plasma ADMA was significantly associated with ADMA in the liver (r = 0.41), but not in the other tissues. In a multivariable regression model, DDAH activities in muscle, kidney, and liver, but not in heart, were negatively associated with plasma ADMA concentration, together explaining approximately 50% of its variation. In critical illness, plasma ADMA poorly reflects intracellular ADMA. Furthermore, tissue DDAH activity is a stronger predictor of plasma ADMA than of intracellular ADMA, indicating that, compared with DDAH activity, generation of ADMA and cationic amino acid transporter-mediated exchange may be more important regulators of intracellular ADMA.     

围产期高盐饮食对雄性子代大鼠肠系膜动脉DDAH2/ADMA/eNOS/NO通路的影响

目的探讨围产期高盐饮食对雄性子代大鼠肠系膜动脉二甲基精氨酸二甲胺水解酶2(DDAH2)/非对称性二甲基精氨酸(ADMA)/内皮型一氧化氮合酶(e NOS)/一氧化氮(NO)通路的影响。方法实验大鼠分为2组:正常饮食(NSD)组和高盐饮食(HSD)组,分别在围产期以普通饲料(含1%Na Cl)和高盐饲料(含8%Na Cl)喂养,分娩后雄性子鼠继续相同饲料喂养至16周。测量子鼠血压,检测肠系膜动脉内皮依赖性舒张功能,检测血浆和肠系膜动脉NO含量、e NOS活性、ADMA含量,检测肠系膜动脉DDAH2活性及DDAH1和DDAH2蛋白质表达水平。结果 16周时,HSD组收缩压显著高于NSD组(P0.01)。HSD组大鼠肠系膜血管张力低于NSD组(P0.01);用ADMA孵育血管环后,NSD组血管张力显著减弱,而HSD组未见显著性变化。与NSD组比较,HSD组血浆NO含量降低(P0.05),e NOS活性降低(P0.01),ADMA含量增加(P0.05);HSD组肠系膜动脉NO含量下降(P0.01),e NOS活性下降(P0.01),ADMA含量升高(P0.05)。HSD组DDAH2活性降低(P0.01),DDAH2蛋白质表达显著降低(P0.01);DDAH1蛋白质表达未见显著改变。HSD组肠系膜动脉指标相关性分析:e NOS活性与NO含量呈正相关,ADMA含量与e NOS活性呈负相关,DDAH2活性、DDAH2蛋白质表达与ADMA含量呈负相关。结论母体围产期高盐饮食导致其雄性子代收缩压增高,肠系膜动脉内皮依赖性舒张功能障碍,此与肠系膜动脉DDAH2表达下降、活性降低和DDAH2/ADMA/e NOS/NO通路障碍有关。     

Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2

Dimethylarginie dimethylaminohydrolase (DDAH) degrades asymmetric dimethylarginine (ADMA), an endogenous nitric oxide (NO) synthase inhibitor, and comprises 2 isoforms, DDAH1 and DDAH2. To investigate the in vivo role of DDAH2, we generated transgenic mice overexpressing DDAH2. The transgenic mice manifested reductions in plasma ADMA and elevations in cardiac NO levels but no changes in systemic blood pressure (SBP), compared with the wild-type mice. When infused into wild-type mice for 4 weeks, ADMA elevated SBP and caused marked medial thickening and perivascular fibrosis in coronary microvessels, which were accompanied by ACE protein upregulation and cardiac oxidative stress. The treatment with amlodipine reduced SBP but failed to ameliorate the ADMA-induced histological changes. In contrast, these changes were abolished in transgenic mice, with a reduction in plasma ADMA. In coronary artery endothelial cells, ADMA activated p38 MAP kinase and the ADMA-induced ACE upregulation was suppressed by p38 MAP kinase inhibition by SB203580. In wild-type mice, long-term treatment with angiotensin II increased plasma ADMA and cardiac oxidative stress and caused similar vascular injury. In transgenic mice, these changes were attenuated. The present study suggests that DDAH2/ADMA regulates cardiac NO levels but has modest effect on SBP in normal conditions. Under the circumstances where plasma ADMA are elevated, including angiotensin II-activated conditions, ADMA serves to contribute to the development of vascular injury and increased cardiac oxidative stress, and the overexpression of DDAH2 attenuates these abnormalities. Collectively, the DDAH2/ADMA pathway can be a novel therapeutic target for vasculopathy in the ADMA or angiotensin II-induced pathophysiological conditions.     

瓜蒌皮提取物对人脐带静脉内皮细胞损伤的保护作用

目的研究瓜蒌皮提取物（EPT）对氧化低密度脂蛋白（OX-LDL）诱导的人脐带静脉内皮细胞（HUVECs）损伤的保护作用。方法在培养的人脐带静脉内皮细胞中加入OX-LDL（100mg／L）诱导内皮细胞损伤。检测细胞培养液中非对称性二甲基精氨酸（ADMA）、丙二醛（MDA）、乳酸脱氢酶（LDH）、一氧化氮（NO）、二甲基精氨酸二甲胺水解酶（DDAH）和肿瘤坏死因子-α（TNF-α）的含量。结果体外给予OX-LDL（100mg／L）显著诱导内皮细胞损伤,提高培养液中ADMA、MDA、LDH、和TNF-α水平,降低NO和DDAH水平。两种洗脱（水和70％乙醇洗脱）瓜蒌皮提取物均能显著抑制OX—LDL所致的ADMA、MDA、LDH和TNF-α浓度升高和NO、DDAH降低。结论瓜蒌皮提取物对OX—LDL诱导的人脐带静脉血管内皮细胞损伤有保护作用,其保护作用与降低ADMA和TNF-α浓度有关。     

Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury.

OBJECTIVES: We sought to determine if a reduction in asymmetric dimethylarginine (ADMA) enhances endothelial regeneration. BACKGROUND: Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS). Increased plasma levels of ADMA are associated with endothelial vasodilator dysfunction in patients with vascular disease or risk factors. Asymmetric dimethylarginine is eliminated largely by the action of dimethylarginine dimethylaminohydrolase (DDAH), which exists in 2 isoforms. Dimethylarginine dimethylaminohydrolase-1 transgenic (TG) mice manifest increased DDAH activity, reduced plasma and tissue ADMA levels, increased nitric oxide synthesis, and reduced systemic vascular resistance. METHODS: The left femoral arteries of DDAH1 TG mice and wild-type (WT) mice were injured by a straight spring wire, and regeneration of the endothelial cell (EC) monolayer was assessed. Endothelial sprouting was assayed with growth factor-reduced Matrigel. RESULTS: Regeneration of the EC monolayer was more complete 1 week after injury in TG mice (WT vs. TG: 40.0 +/- 6.5% vs. 61.2 +/- 6.4%, p < 0.05). The number of CD45 positive cells at the injured sites was reduced by 62% in DDAH TG mice (p < 0.05). Four weeks after injury, the neointima area and intima/media ratio were attenuated in DDAH TG mice (WT vs. TG: 0.049 +/- 0.050 mm2 vs. 0.031 +/- 0.060 mm2, 3.1 +/- 0.5 vs. 1.7 +/- 0.2, respectively, p < 0.05). Endothelial cell sprouting from vascular segments increased in TG mice (WT vs. TG: 24.3 +/- 3.9 vs. 39.0 +/- 2.2, p < 0.05). CONCLUSIONS: We find for the first time an important role for DDAH in EC regeneration and in neointima formation. Strategies to enhance DDAH expression or activity might be useful in restoring the endothelial monolayer and in treating vascular disease.     

Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA)

Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) are found in various clinical settings, including renal failure, coronary heart disease, hypertension, diabetes and pre-eclampsia. In healthy people acute infusion of ADMA promotes vascular dysfunction, and in mice chronic infusion of ADMA promotes progression of atherosclerosis. Thus, ADMA may not only be a marker but also an active player in cardiovascular disease, which makes it a potential target for therapeutic interventions. This review provides a summary and critical discussion of the presently available data concerning the effects on plasma ADMA levels of cardiovascular drugs, hypoglycemic agents, hormone replacement therapy, antioxidants, and vitamin supplementation. We assess the evidence that the beneficial effects of drug therapies on vascular function can be attributed to modification of ADMA levels. To develop more specific ADMA-lowering therapies, mechanisms leading to elevation of plasma ADMA concentrations in cardiovascular disease need to be better understood. ADMA is formed endogenously by degradation of proteins containing arginine residues that have been methylated by S-adenosylmethionine-dependent methyltransferases (PRMTs). There are two major routes of elimination: renal excretion and enzymatic degradation by the dimethylarginine dimethylaminohydrolases (DDAH-1 and -2). Oxidative stress causing upregulation of PRMT expression and/or attenuation of DDAH activity has been suggested as a mechanism and possible drug target in clinical conditions associated with elevation of ADMA. As impairment of DDAH activity or capacity is associated with substantial increases in plasma ADMA concentrations, DDAH is likely to emerge as a prime target for specific therapeutic interventions.     

Hydrogen‐rich saline protects against liver injury in rats with obstructive jaundice

Background: Hydrogen selectively reduces levels of hydroxyl radicals and alleviates acute oxidative stress in many models. Hydrogen‐rich saline provides a high concentration of hydrogen that can be easily and safely applied. Aims: In this study, we investigated the effects of hydrogen‐rich saline on the prevention of liver injury induced by obstructive jaundice in rats. Methods: Male Sprague–Dawley rats (n=56) were divided randomly into four experimental groups: sham operated, bile duct ligation (BDL) plus saline treatment [5 ml/kg, intraperitoneal (i.p.)], BDL plus low‐dose hydrogen‐rich saline treatment (5 ml/kg, i.p.) and BDL plus high‐dose hydrogen‐rich saline treatment (10 ml/kg, i.p.). Results: The liver damage was evaluated microscopically 10 days after BDL. Serum alanine aminotransferase and aspartate aminotransferase levels, tissue malondialdehyde content, myeloperoxidase activity, tumour necrosis factor‐α, interleukin (IL)‐1β, IL‐6 and high‐mobility group box 1 levels were all increased significantly by BDL. Hydrogen‐rich saline reduced levels of these markers and relieved morphological liver injury. Additionally, hydrogen‐rich saline markedly increased the activities of anti‐oxidant enzymes superoxide dismutase and catalase and downregulated extracellular signal‐regulated protein kinase (ERK)1/2 activation. Conclusions: Hydrogen‐rich saline attenuates BDL‐induced liver damage, possibly by the reduction of inflammation and oxidative stress and the inhibition of the ERK1/2 pathway.     

Melatonin exerts a therapeutic effect on cholestatic liver injury in rats with bile duct ligation

We examined whether melatonin exerts a therapeutic effect on cholestatic liver injury in rats treated with bile duct ligation (BDL). Cholestatic liver injury was induced in male Wistar rats aged 4 wk by ligating the bile duct. Cholestatic liver injury developed 5 days after BDL and continued to 13 days, judging from the levels of serum hepatobiliary injury markers. The serum concentration of thiobarbituric acid reactive substances (TBARS), an index of lipid peroxidation, and the hepatic level of TBARS and the activity of hepatic myeloperoxidase, an index of tissue neutrophil infiltration, increased 5 days after BDL, and these increases were enhanced at 13 days. A similar increase in the serum total cholesterol concentration occurred 5 and 13 days after BDL, while the hepatic cholesterol concentration tended to increase at 13 days. When melatonin [10 or 100 mg/kg body weight (BW)] was orally administered to BDL-treated rats everyday for 8 days, starting 5 days after BDL, the indoleamine attenuated cholestatic liver injury observed at 13 days after BDL was more effective at the higher dose than at the lower dose. The administered melatonin (10 or 100 mg/kg BW) reduced the increases in serum and hepatic TBARS concentrations and hepatic myeloperoxidase activity observed at 13 days after BDL and the higher dose of indoleamine was more effective than the lower dose. Neither dose of melatonin affected the increased serum total cholesterol concentration or the hepatic cholesterol concentration observed at 13 days after BDL. These results indicate that orally administered melatonin at pharmacological doses exerts a therapeutic effect on cholestatic liver injury in rats with BDL possibly through its antioxidant and anti-inflammatory actions.     

Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase

In response to vascular insults, inflammatory cytokines stimulate vascular smooth muscle cells (SMCs) to express an inducible isoform of nitric oxide synthase (iNOS). Asymmetric dimethylarginine (ADMA), an endogenous NO synthase inhibitor, is metabolized by dimethylarginine dimethylaminohydrolase (DDAH). To determine whether the ADMA-DDAH system regulates cytokine-induced NO production, cultured rat SMCs were exposed to interleukin-1beta (IL-1beta). IL-1beta (1 to 100 U/mL) dose-dependently stimulated not only iNOS but also DDAH expression and enzyme activity, accompanied by an increase in NO metabolite and by a decrease in ADMA content in culture media. A DDAH inhibitor (4124W, 5 mmol/L) augmented ADMA production (P<0.01) and decreased NO synthesis (P<0.01) in IL-1beta-stimulated SMCs. On the other hand, an adenovirus-mediated overexpression of DDAH reduced ADMA and enhanced NO production. Exogenous administration of NO donors (SNAP and SIN-1) dose-dependently increased NO metabolite in the culture media but had no effect on ADMA. Our results indicate two mechanisms of IL-1beta-induced NO synthesis: the direct stimulation of the expression of iNOS and the indirect stimulation of iNOS activity by upregulating DDAH and reducing ADMA. The ADMA-DDAH system may be another regulatory mechanism of inflammation-mediated NO production for human vascular diseases.     

Changes in Serum Asymmetric Dimethylarginine and Endothelial Markers Levels With Varying Periods of Hemodialysis

Asymmetric dimethylarginine (ADMA) as a uremia toxin is accumulated in end‐stage renal disease (ESRD) patients. Elevated ADMA level has been shown to be predictive of cardiovascular diseases (CVDs) and all‐cause mortality in ESRD. Therefore, we investigated the effect of prolonged hemodialysis (HD) treatment on the levels of serum ADMA, arginine, nitric oxide (NO), soluble intercellular adhesion molecule‐1 (sICAM‐1) and soluble vascular cell adhesion molecule‐1 (sVCAM‐1). Seventy‐five patients (M/F = 40/35) with chronic renal failure (CRF) and who were on HD were divided into five groups with differing treatment periods of HD; from 6 to 24 months to 97–120 months. Fifteen apparently healthy subjects acted as controls. The serum levels of ADMA, sICAM‐1 and sVCAM‐1 were increased in all patient groups compared to the control group. No significant difference was observed when the patient groups were compared in terms of HD treatment periods. Nitric oxide levels were lower in the three groups who were treated for periods of 49–72, 73–96, 97–120 months compared to the control group. The L‐arginine to ADMA ratio was decreased in all patient groups compared to controls. Consequently, our investigations have shown that in HD continued for more than 4 years NO levels began to decrease significantly and the levels of serum ADMA, sICAM‐1 and sVCAM‐1 levels increased although this increase was not affected by the period in which hemodialysis treatment was applied.     

The DDAH/ADMA/NOS pathway

An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS), particularly asymmetric dimethylarginine (ADMA) regulate nitric oxide generation in numerous disease states. Two dimethylarginine dimethylaminohydrolase (DDAH) enzymes metabolise ADMA. We and others have postulated that activity of DDAH is a key determinant of ADMA levels in vivo. This review summarises recent advances in the regulation and function of DDAH enzymes and its role in the regulation of nitric oxide generation.